Organon & Co. (NYSE:OGN) Receives Average Rating of “Reduce” from Brokerages

Shares of Organon & Co. (NYSE:OGN) have earned a consensus rating of “Reduce” from the seven research firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.50.

Several equities analysts have recently commented on OGN shares. Barclays boosted their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. JPMorgan Chase & Co. lowered their price target on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, November 11th. Zacks Research downgraded Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Morgan Stanley reduced their price objective on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 11th. Finally, Wall Street Zen lowered shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st.

Hedge Funds Weigh In On Organon & Co.

Several institutional investors have recently added to or reduced their stakes in OGN. GAMMA Investing LLC lifted its holdings in shares of Organon & Co. by 22.4% in the 3rd quarter. GAMMA Investing LLC now owns 6,910 shares of the company’s stock worth $74,000 after acquiring an additional 1,265 shares during the last quarter. Rexford Capital Inc. raised its position in Organon & Co. by 14.9% in the 3rd quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock worth $122,000 after purchasing an additional 1,480 shares during the period. Amalgamated Bank raised its position in Organon & Co. by 1.9% in the 3rd quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock worth $852,000 after purchasing an additional 1,514 shares during the period. State of Alaska Department of Revenue lifted its stake in Organon & Co. by 0.6% in the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock worth $1,995,000 after purchasing an additional 1,570 shares during the last quarter. Finally, Integrated Wealth Concepts LLC boosted its position in shares of Organon & Co. by 2.8% during the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after buying an additional 1,594 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $7.14 on Monday. The company has a market capitalization of $1.86 billion, a P/E ratio of 9.99, a P/E/G ratio of 0.66 and a beta of 0.61. Organon & Co. has a 1-year low of $6.18 and a 1-year high of $16.08. The firm’s 50 day simple moving average is $7.99 and its two-hundred day simple moving average is $8.46. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The firm had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the previous year, the business earned $0.90 earnings per share. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. Research analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Monday, February 23rd. Organon & Co.’s payout ratio is 11.27%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.